Brief: Appili Therapeutics Announces Alignment With FDA On Development Requirements For Ati-1801 Topical Antiparasitic Product NDA Submission
31/10/2024 11:17
Oct 31 (Reuters) -
* APPILI THERAPEUTICS ANNOUNCES ALIGNMENT WITH FDA ON
DEVELOPMENT
REQUIREMENTS FOR ATI-1801 TOPICAL ANTIPARASITIC PRODUCT NDA
SUBMISSION
Source text: ID:nGNX4Fz408
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Appili Therapeutics
See all newsBrief: Appili Therapeutics Announces Closing Of Second Tranche Of Non-Brokered Private Placement
Brief: Appili Therapeutics Closes First Tranche Of Non-Brokered Private Placement
Brief: Appili Therapeutics Announces Proposed Non-Brokered Private Placement
Brief: Appili Therapeutics Announces Formal Termination Of Arrangement Agreement With Aditxt
Brief: Appili Therapeutics Announces New Patents Granted For Commercial Stage Asset Likmez